Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01495221 · ClinicalTrials.gov registry record · Phase 4
To Evaluate The Role of Intravitreal Aflibercept Injection (2.0 mg) in the Management of Previously Treated Patients With Exudative AMD
A Phase 4 study of AMD (With Persistent or Recurrent Fluid Despite Monthly Intravitreal Anti-VEGF Therapy), sponsored by Vitreous -Retina- Macula Consultants of New York.
- Completed
- Registry status
- Phase 4
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT01495221: Completed Phase 4 study of AMD (With Persistent or Recurrent Fluid Despite Monthly Intravitreal Anti-VEGF Therapy), sponsored by Vitreous -Retina- Macula Consultants of New York.
NCT01495221 is a Phase 4 study of AMD (With Persistent or Recurrent Fluid Despite Monthly Intravitreal Anti-VEGF Therapy) that has completed, run by Vitreous -Retina- Macula Consultants of New York. The registered enrollment target is 9 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01495221, a Phase 4 study of AMD (With Persistent or Recurrent Fluid Despite Monthly Intravitreal Anti-VEGF Therapy), has completed, sponsored by Vitreous -Retina- Macula Consultants of New York.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open label study to evaluate intravitreally administered 2.0 mg intravitreal aflibercept injection in patients who have been previously treated for AMD and have persistent or recurrent fluid despite monthly intravitreal anti-VEGF therapy.
Primary Outcome
No primary outcome data can be found or provided.
Conditions Studied
Interventions
- DRUG Alfilbercept
Study Locations (1)
New York
- Vitreous Retina Macula Consultants of New York - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2011-12 |
| Est. Completion | 2013-03 |
| Phase | Phase 4 |
What the finished NCT01495221 record still lists
NCT01495221 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower).
The record links to 1 condition, with AMD (With Persistent or Recurrent Fluid Despite Monthly Intravitreal Anti-VEGF Therapy) appearing as the primary indexed condition, and to 1 intervention - of which Alfilbercept is the first listed.
NCT01495221 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT01495221 about?
NCT01495221 is a clinical study titled "To Evaluate The Role of Intravitreal Aflibercept Injection (2.0 mg) in the Management of Previously Treated Patients With Exudative AMD". This is an open label study to evaluate intravitreally administered 2.0 mg intravitreal aflibercept injection in patients who have been previously treated for AMD and have persistent or recurrent fluid despite monthly intravitreal anti-VEGF therapy.
What is the current status of trial NCT01495221?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 9 participants. The study started on 2011-12. Estimated completion is 2013-03.
What conditions does trial NCT01495221 study?
This clinical trial studies the following conditions: AMD (With Persistent or Recurrent Fluid Despite Monthly Intravitreal Anti-VEGF Therapy).
What interventions are being tested in trial NCT01495221?
The interventions under investigation include: Alfilbercept (DRUG).
Who is sponsoring clinical trial NCT01495221?
This trial is sponsored by Vitreous -Retina- Macula Consultants of New York, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01495221 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01495221's enrollment target sits among peer trials
9 1968th of 2000 higher than 29 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia